Surgalign Holdings, Inc. (SRGA)
Stock Price Chart
Key Info
| Market Cap | 139.77M |
| Revenue (ttm) | 284.29M |
| Net Income (ttm) | -259.73M |
| Shares Out | 75.15M |
| EPS (ttm) | -3.54 |
| PE Ratio | n/a |
| Forward PE | 526.32 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Oct 28, 2020 |
| Last Price | $1.86 |
| Previous Close | $1.92 |
| Change ($) | -0.06 |
| Change (%) | -3.13% |
| Day's Open | 1.89 |
| Day's Range | 1.80 - 1.90 |
| Day's Volume | 446,129 |
| 52-Week Range | 1.46 - 5.40 |
More Stats
| Market Cap | 139.77M |
| Enterprise Value | 326.67M |
| Earnings Date (est) | May 6, 2021 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 75.15M |
| Float | 68.52M |
| EPS (basic) | -3.54 |
| EPS (diluted) | -3.54 |
| FCF / Share | -0.34 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 1.77M |
| Short Ratio | 3.41 |
| Short % of Float | 2.58% |
| Beta | 1.89 |
| PE Ratio | n/a |
| Forward PE | 526.32 |
| P/FCF Ratio | n/a |
| PS Ratio | 0.49 |
| PB Ratio | 12.54 |
| Revenue | 284.29M |
| Operating Income | -217.32M |
| Net Income | -259.73M |
| Free Cash Flow | -25.76M |
| Net Cash | -186.89M |
| Net Cash / Share | -2.49 |
| Gross Margin | 61.35% |
| Operating Margin | -76.44% |
| Profit Margin | -91.40% |
| FCF Margin | -9.06% |
| ROA | -3.37% |
| ROE | -147.31% |
| ROIC | -91.20% |
Analyst Forecasts
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 308 | 280 | 280 | 276 | 282 | 263 | 198 | 178 | 169 | 166 |
| Revenue Growth | 9.99% | 0% | 1.58% | -2.23% | 7.41% | 32.75% | 11.15% | 5.2% | 1.89% | - |
| Gross Profit | 171 | 140 | 143 | 133 | 150 | 134 | 80.11 | 85.22 | 77.21 | 76.00 |
| Operating Income | -182 | -4.31 | -4.75 | -15.26 | 24.63 | 5.63 | -28.66 | 12.24 | 11.77 | -127 |
| Net Income | -212 | -3.12 | 6.91 | -13.81 | 14.92 | 2.70 | -17.81 | 8.40 | 8.38 | -129 |
| Shares Outstanding | 72.82 | 63.52 | 59.68 | 58.24 | 57.61 | 56.74 | 56.26 | 55.86 | 55.15 | 54.73 |
| Earnings Per Share | -2.91 | -0.08 | 0.05 | -0.30 | 0.20 | -0.01 | -0.34 | 0.15 | 0.15 | -2.36 |
| EPS Growth | - | - | - | - | - | - | - | 0% | - | - |
| Operating Cash Flow | -9.46 | 17.25 | 5.79 | 15.32 | 9.00 | 6.89 | -4.45 | 20.80 | 27.77 | 29.39 |
| Capital Expenditures | -14.43 | -11.04 | -10.48 | -15.34 | -17.74 | -15.58 | -15.01 | -11.09 | -6.35 | -3.24 |
| Free Cash Flow | -23.88 | 6.21 | -4.70 | -0.01 | -8.74 | -8.68 | -19.47 | 9.71 | 21.42 | 26.15 |
| Cash & Equivalents | 5.61 | 10.95 | 22.38 | 13.85 | 12.61 | 15.70 | 18.72 | 49.70 | 46.18 | 28.21 |
| Total Debt | 174 | 49.07 | 46.34 | 83.35 | 79.24 | 75.89 | 69.05 | 0.12 | 0.59 | 3.00 |
| Net Cash / Debt | -169 | -38.12 | -23.96 | -69.50 | -66.62 | -60.19 | -50.33 | 49.58 | 45.59 | 25.22 |
| Assets | 345 | 360 | 346 | 368 | 381 | 378 | 370 | 241 | 230 | 226 |
| Liabilities | 244 | 112 | 100 | 143 | 143 | 157 | 152 | 57.42 | 57.61 | 63.82 |
| Book Value | 34.56 | 182 | 182 | 165 | 181 | 168 | 168 | 184 | 172 | 162 |
Company Profile
Company Details
| Full Name | Surgalign Holdings, Inc. |
| Country | United States |
| Employees | 935 |
| CEO | Terry M. Rich |
Stock Information
| Ticker Symbol | SRGA |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Unique Identifier | NASDAQ: SRGA |
| IPO Date | August 10, 0200 |
Description
Surgalign Holdings, a medical technology company, designs, develops, manufactures, and distributes biologic, metal, and synthetic implants worldwide. It offers coflex interlaminar stabilization device, an implant for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression; SImmetry sacroiliac joint fusion system, which decreases in opioid use, pain, and disability; and Fortilink IBF system with TETRAfuse ?3D technology. The company's implants are used in the fields of orthopedic, spine, sports medicine, plastic surgery, trauma, and other surgical procedures to repair and promote the natural healing of human bone and other human tissues; and to enhance surgical outcomes. It markets its products through its direct distribution force and various OEM relationships to healthcare providers, hospitals, and other healthcare facilities, as well as through a network of independent distributors. The company was founded in 1997 and is headquartered in Deerfield, Illinois.